Immunologically specific rejection of syngeneic tumours by experimental animals which have been immunized is well established, and there are many reports which show that the immune state can be transferred by lymphoid cells. The nature of the effector mechanisms is complex and not only may vary from one tumour system to another but also may depend on the anatomical site of tumour implantation. The role of macrophages in rejection reactions, particularly allografts, was remarked upon by Gorer (1956) and later demonstrated with in-vitro techniques by Granger and Weiser (1964) . Our attention focused on the role of macrophages in rejection of syngeneic ascitic lymphomas to which immunity can be induced by injection of x-irradiated cells but the lymphoid cells from hyperimmunized mice behaved in a seemingly paradoxical manner when mixed with the specific lymphoma cells. When the cell mixtures were injected into normal DBA/2 mice growth of the tumour cells was arrested, but when the mixtures were incubated in culture, the lymphoma cells grew normally in the presence of the lymphoid cells from hyperimmunized mice (Alexander, Connell, and Mikulska, 1966) . We were led to the hypothesis that with these particular syngeneic tumours, their injection together with immune lymphoid cells required a cooperation with other and non-immune cells, such as macrophages, to produce rejection (Evans and Alexander, 1970) .
The 'Armed' and the 'Activated' Macrophage Support for this concept was provided by experiments in which it was shown that macrophages which inhibit the growth of tumour cells in an immunologically specific way in vitro can be obtained in three ways: (1) directly from the peritoneal cavity of hyperimmunized mice (Evans and Alexander, 1 972a); (2) by incubation of non-immune macrophages with spleen cells from hyperimmune mice (Evans and Alexander, 1970, 1972a) ; (3) by treatment of nonimmune macrophages with a factor called 'specific macrophage arming factor' (SMAF) which is produced by immune T-cells after they have been incubated for some hours with the specific antigen (Evans and Alexander, 1971, 1972b; Evans, Grant, Cox, Steele, and Alexander, 1972) . The term 'arming' is used to describe the process whereby macrophages acquire in vitro the capacity to inhibit the growth of and kill target cells in an immunologically specific manner. Lymphoid cells from singly immunized mice failed to arm macrophages, even though the mice were strongly immune to challenge with dividing lymphoma cells, and peritoneal macrophages from these mice were only weakly cytotoxic. However, the same lymphoid cells when exposed to the specific lymphoma cells released a factor which was able to arm normal macrophages suggesting that singly immunized mice required a second exposure to antigen before immune peritoneal macrophages and arming lymphoid cells could be demonstrated.
The growth inhibitory action of macrophages from suitably immunized animals or 'armed' in vitro can be directed against the normal transplantation antigen of the tumour cells or in syngeneic systems against the tumour-specific antigens. Such macrophages exert their action by membrane contact with the target cell. Phagocytosis is a late event which occurs only after the target cell has been killed. Immune or armed macrophages following incubation with the specific antigen undergo a change which we have called 'activation' (Evans and Alexander, 1972c) , after which they acquire the property to inhibit in vitro the growth of all sarcoma and lymphoma cells tested by us.' This transition from arming to activation is illustrated diagrammatically in figure 1. inhibit the growth in vitro of lymphoma and sarcoma cells but have no effect on the growth of rapidly dividing embryo fibroblasts. Remington's group reported that macrophages obtained from mice infected with Toxoplasma inhibited the growth of the long-established line of mouse fibroblasts (L-cells) which can be considered to be malignant cells but had no effect on the growth of mouse embryo cells (Hibbs, Lambert, and Remington, 1972a) . However, when after prolonged culture the embryo cells developed an abnormal growth pattern then they became susceptible to inhibition by activated macrophages (Hibbs, Lambert, and Remington, 1972b (Evans and Alexander, 1972c ). Transformation from an armed to an activated state by contact with specific antigen also occurs in vivo (Evans and Alexander, 1972c; Alexander, Evans, and Grant, 1972) . Figure 2 shows that when mice are immunized three times with SL2 cells and the macrophages taken 10 days after the last immunization they are specifically cytotoxic, ie, they affect SL2 cells but not TLX9 (1972a) who found that following infection with Toxoplasma, peritoneal macrophages of mice with active toxoplasmosis were cytotoxic to tumour cells in vitro, ie, these macrophages were activated. These workers also showed that mice with activated macrophages due to toxoplasmosis were more resistant to challenge with tumour cells (Hibbs, Lambert, and Remington, 1972c) and to viral carcinogenesis (Hibbs, Lambert, and Remington, 1972d) . We made the same observavation by accident (Evans and Alexander, 1972c) : our mouse colony became infected with Pasteurella which persisted in the mice for months; the macrophages from such mice were non-specifically cytotoxic. Macrophages can also be 'activated', ie, inhibit the growth of sarcoma and lymphoma cells in an immunologically non-specific way by exposure, in vitro or in vivo, to very low concentrations of endotoxin or double-stranded RNA (see fig 3) . Such in the peritoneal cavity. That macrophages may also be involved in the reaction of the syngeneic host to solid tumours is indicated by the finding of Evans (1972) that sarcomas in mice and rats may contain more than 50 % of macrophages. These macrophages are difficult to recognize histologically and the identification of cells in a tumour as macrophages relied on testing the cells from a tumour after they had been brought into suspension by trypsinization.
The criteria for identification and characterization of tumour macrophages were (1) rapid, ie, within five minutes at 37°C, adherence and spreading either in the haemocytometer or in culture vessels. After fixation in methanol and staining these cells were typically monocytic and polymorphs, when present, never exceeded 10% of the total macrophage population; (2) resistance to detachment by trypsinization; (3) the ability to phagocytose colloidal carbon rapidly; (4) the ability to phagocytose the murine lymphoma cells in the presence of alloantiserum; (5) lysis by rabbit antimouse macrophage serum (AMS) in the presence of complement.
Evans (1972) showed that the macrophages in the tumour were derived from the host. Tumours were produced by inoculation of (a) a cell suspension derived from the tumour and containing both tumour cells and macrophages, and of (b) a cell suspension from which the macrophages had been eliminated by treatment in vitro with anti-macrophage serum.
By 14 days the macrophage content of the tumours derived from an inoculum of tumour cells without macrophages was the same as those which had grown from cell inoculum containing 30% of macrophages.
Macrophages may also be involved in the phenomenon of concomitant immunity (Alexander, Evans, and Mikulska, 1973) , ie, the situation in which an animal with a growing tumour is able to reject a second inoculum of the same tumour at a distant site in spite of the fact that the primary tumour is growing relentlessly. The relevance of concomitant immunity to metastatic spread is obvious. Figure 4 shows the results from an experiment in which DBA/2 mice were inoculated subcutaneously with graded doses of syngeneic lymphoma cells and were then injected two weeks later with 103 lymphoma cells administered intraperitoneally. This intraperitoneal challenge, which gives rise to an ascites tumour in 100% of untreated normal mice and kills them within 24 days, did not grow in any of the animals that had previously been injected with 105 living tumour cells subcutaneously. The protection of the peritoneal cavity was apparently related to the size of the subcutaneous tumour, since if the intraperitoneal challenge was given only seven days after the inoculation of 105 cells subcutaneously-as opposed to 14 days as shown in fig 4-no protection was observed and all of the mice died with an ascitic tumour. The introduction of viable tumour cells intraperitoneally does not hasten the death of animals from their subcutaneous tumour and, indeed, there is some indication that it may slow it.
Tests in vitro showed that the peritoneal cavity of the mice bearing subcutaneously growing lymphomata contained macrophages which inhibited the growth of the lymphoma cells and that the draining nodes contained lymphocytes capable of arming macrophages against the lymphoma cells (Alexander, Evans, and Mikulska, 1973) . These data are consistent with the hypothesis that the resistance of the peritoneal cavity to tumour growth in a tumour-bearing animal is mediated by macrophages. Evans and Alexander, 1971 ).
possible to protect with PPD given intravenously against a tumour challenge injected intravenously into mice sensitized to BCG. This experiment may be an example of the phenomenon in man described earlier by Klein (1969) . He found that some skin tumours regress following painting or injection of an antigen to which the patient had been sensitized, eg, DNCB painting in DNCB-sensitized subjects or PPD injection into tumours of tuberculin-sensitive subjects. It must be stressed that the practical usefulness of all such treatments is limited because macrophage activation is largely confined to the site (or the node draining the site) into which the antigen had been injected. Hence, this procedure, as Klein has found, can only be used for the eradication of accessible tumours. An antitumour action in vivo could also be demonstrated by transferring specifically growth-inhibitory macrophages to mice bearing an ascites tumour (Alexander, Evans, and Mikulska, 1973) . Peritoneal cells were removed from mice that had been immunized twice with irradiated L5178Y cells and were then grown for 48 hours on sheets of collagen prepared from rat tails. These cultures were then washed extensively and the cells detached by incubation with collagenase. The cell suspension obtained was totally free from lymphocytes. Table III shows that injection of immune macrophages two days after an intraperitoneal inoculation of 103 lymphoma (L5178Y) cells reduced the rate of growth of the tumour in vivo. Since an inoculum of 10 cells kills DBA/2 mice in 35 days we may deduce that the immune macrophages killed about 99 % of the 10" tumour cells that are present in the peritoneal cavity two days after the challenge with 103 cells. Nonimmune macrophages prepared in the same way did not influence the growth of this tumour.
